Why Insys Therapeutics’ Stock Crashed 18.5% in August

By:
Why Insys Therapeutics' Stock Crashed 18.5% in August

Pixabay / PIX1861 / CC0 Public Domain

What happened
Arizona’s attorney general is suing Insys Therapeutics (NASDAQ:INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company’s shares to tumble 18.5% in August, according to S&P Global Market Intelligence.

So what
Insys Therapeutics has launched its marijuana drug Syndros. However, uncertainty over demand for it and ongoing concerns regarding the marketing of Subsys remain major headwinds.

Now what
Insys Therapeutics’ shares rallied briefly after management announced a $4.5 million settlement.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts

Top